Extranodal marginal zone B-cell lymphoma (MALT type) – Diagnostics – Overview of Information and Clinical Research

Diagnosing extranodal marginal zone B-cell lymphoma (MALT lymphoma) requires a careful combination of physical examination, tissue sampling, blood tests, and imaging studies to confirm the disease and understand its extent throughout the body.

Introduction: Who Should Undergo Diagnostics

Anyone experiencing persistent symptoms that could point to MALT lymphoma should consider seeking medical evaluation. Since this type of lymphoma often develops slowly and may not cause noticeable symptoms in its early stages, many people are diagnosed during routine examinations or tests performed for unrelated health issues.^[1] The condition most commonly affects people aged 60 and older, with a slight preference for males over females.^[1]

It is especially important to seek diagnostic testing if you have symptoms related to the stomach, such as ongoing indigestion, heartburn, unexplained weight loss, nausea, vomiting, or belly pain. These symptoms can suggest gastric MALT lymphoma, which is the most common form of this disease and often develops in the stomach.^[8] However, MALT lymphoma can also appear in other parts of the body, including the lungs, eyes, salivary glands, thyroid, or skin, each producing different symptoms depending on where the disease starts.^[3]

People with certain risk factors should be particularly alert to symptoms and seek early evaluation. These risk factors include a history of infection with Helicobacter pylori (a bacteria that causes stomach inflammation), hepatitis C virus, or other bacterial infections. Additionally, those with autoimmune conditions such as Sjögren’s syndrome or Hashimoto’s thyroiditis face increased risk, as these disorders can trigger chronic inflammation that may eventually lead to lymphoma development.^[5] A family history of lymphoma or other blood cancers also raises your risk and warrants closer attention to potential warning signs.^[3]

For gastric MALT lymphoma specifically, anyone diagnosed with Helicobacter pylori infection should discuss with their doctor whether additional testing is needed, even if symptoms are mild. This is because the connection between H. pylori and gastric MALT lymphoma is well established, and early detection can lead to better outcomes.^[4]

⚠️ Important

MALT lymphoma develops slowly and may not cause symptoms early on. Many patients discover they have the condition accidentally during tests for other health problems. If you have persistent unexplained symptoms or known risk factors such as chronic H. pylori infection or autoimmune disease, speak with your doctor about appropriate screening.

Classic Diagnostic Methods

Biopsy: The Gold Standard

The main test used to diagnose MALT lymphoma is a biopsy, which involves removing a small sample of tissue from the affected area and examining it under a microscope. A specialist in the laboratory looks for abnormal B lymphocytes that are characteristic of this type of lymphoma. The biopsy is essential because it confirms the diagnosis and helps distinguish MALT lymphoma from other conditions that may cause similar symptoms.^[8]

The method used to obtain the biopsy depends on where the suspected lymphoma is located. For gastric MALT lymphoma, which starts in the stomach, doctors perform a gastroscopy (also called an endoscopy). During this procedure, a thin, flexible tube with a camera on the end is passed through the mouth and down into the stomach. The doctor can see the inside of the stomach directly and take small tissue samples from any areas that look abnormal.^[15]

When MALT lymphoma is suspected in the lungs, a bronchoscopy may be performed. This involves passing a similar tube through the nose or mouth into the airways to collect tissue samples. For lymphoma in the bowel, a colonoscopy allows the doctor to examine the inside of the large intestine and take biopsies if needed.^[8] If the lymphoma appears in more accessible locations like the skin or near the surface of the body, a simple surgical biopsy or needle biopsy may be sufficient.^[5]

Blood Tests

While a biopsy confirms the diagnosis, blood tests provide important additional information about the disease and the patient’s overall health. A complete blood count (CBC) measures the levels of different blood cells, including red blood cells, white blood cells, and platelets. This test can reveal if the lymphoma has affected the bone marrow, where blood cells are produced.^[5]

Doctors also check levels of lactate dehydrogenase (LDH), an enzyme that can be elevated when cells are damaged or destroyed. High LDH levels may suggest more active or widespread disease. Another blood test measures beta-2 microglobulin, a protein that serves as a tumor marker for blood cancers. Elevated levels can indicate a higher disease burden.^[5]

Liver and kidney function tests are routinely performed to assess how well these organs are working. This information is important both for understanding the extent of the disease and for planning treatment, since some medications are processed by the liver or kidneys.^[12]

For gastric MALT lymphoma, testing for Helicobacter pylori infection is crucial. This can be done through blood tests that detect antibodies against the bacteria, or through analysis of tissue samples taken during the gastroscopy. Identifying H. pylori infection is vital because treating the infection with antibiotics can sometimes eliminate the lymphoma completely without the need for cancer-specific therapy.^[15]

Imaging Studies

After MALT lymphoma is diagnosed through biopsy, imaging tests help determine how far the disease has spread. This process, called staging, is essential for choosing the right treatment approach. Most patients with MALT lymphoma are diagnosed at an early stage, with the disease limited to one area, but imaging helps confirm this and identifies any unexpected spread.^[1]

Computed tomography (CT) scans are commonly used to create detailed cross-sectional images of the body. A CT scan of the chest, abdomen, and pelvis can show whether lymph nodes or organs in these areas are enlarged or affected by lymphoma. The test is painless, though it may require drinking a contrast liquid or receiving an injection that helps certain tissues show up more clearly on the images.^[1]

In some cases, doctors may use positron emission tomography (PET) scans, which detect areas of high metabolic activity in the body. Cancer cells typically use more energy than normal cells, so they appear as bright spots on a PET scan. This test can be particularly helpful in detecting small areas of disease or assessing how well treatment is working.^[1]

Ultrasound examinations use sound waves to create images of internal organs and can be useful for evaluating lymphoma in specific locations, such as the thyroid gland or areas around the eye.^[1]

Bone Marrow Examination

A bone marrow aspirate and biopsy may be performed to check whether lymphoma cells have spread to the bone marrow, the spongy tissue inside bones where blood cells are made. This procedure involves inserting a needle into the hip bone to remove a small sample of bone marrow. While it can be uncomfortable, it provides valuable information about disease extent. Bone marrow involvement is more common in certain locations of MALT lymphoma, particularly those affecting the lungs or areas around the eyes.^[7]

Endoscopic Investigations

For gastric MALT lymphoma, the gastroscopy serves a dual purpose: it allows the doctor to see the inside of the stomach and to take biopsies. During this examination, doctors look for areas of redness, swelling, ulceration, or other abnormalities that might indicate lymphoma or the underlying H. pylori infection that often causes it.^[8]

Beyond the stomach, endoscopic examinations can evaluate other parts of the digestive system if needed. These procedures help establish the exact location and extent of lymphoma involvement, which is critical for treatment planning.^[1]

Special Laboratory Tests

Tissue samples obtained through biopsy undergo specialized testing beyond basic microscopy. Immunohistochemistry uses antibodies to identify specific proteins on the surface of lymphoma cells. MALT lymphoma cells typically show certain markers (such as CD19, CD20, and CD22) and lack others (such as CD5, CD10, and CD23). This pattern helps distinguish MALT lymphoma from other types of lymphoma.^[19]

Flow cytometry is another technique that analyzes the characteristics of cells in a sample. It can detect abnormal lymphocytes and help confirm the diagnosis. In some cases, genetic tests look for specific chromosomal changes that are common in MALT lymphoma, such as translocations involving chromosomes 11 and 18. These genetic findings can provide additional diagnostic certainty and may have implications for prognosis.^[1]

Distinguishing MALT Lymphoma from Other Conditions

One of the key challenges in diagnosing MALT lymphoma is distinguishing it from other conditions that can look similar. Chronic inflammation from infections or autoimmune diseases can create reactive lymphoid tissue that resembles lymphoma under the microscope. This is why demonstrating that the B cells are abnormal and clonal (all descended from a single abnormal cell) is so important. Tests that show immunoglobulin light chain restriction help confirm that the lymphocytes are malignant rather than simply reacting to inflammation.^[7]

MALT lymphoma must also be differentiated from other types of small B-cell lymphomas, including follicular lymphoma, mantle cell lymphoma, and small lymphocytic lymphoma. Each has distinct characteristics under the microscope and different patterns of surface markers, which is why the specialized tests mentioned above are so valuable.^[7]

Diagnostics for Clinical Trial Qualification

When patients with MALT lymphoma are being considered for participation in clinical trials testing new treatments, they undergo a standardized set of diagnostic tests. These tests serve multiple purposes: they confirm eligibility for the trial, establish a baseline measure of disease extent, and ensure that patients are healthy enough to safely receive the experimental treatment.^[1]

Clinical trials typically require confirmation of the MALT lymphoma diagnosis through pathology review. This means that tissue samples from the original biopsy are re-examined by specialized pathologists to verify the diagnosis and ensure that the patient truly has MALT lymphoma rather than another condition. The review often includes immunohistochemistry and may involve genetic testing to identify specific chromosomal abnormalities.^[1]

Staging procedures are mandatory for trial enrollment. Complete staging usually involves CT scans of the chest, abdomen, and pelvis to document all areas affected by lymphoma. Some trials require PET scans as well, particularly those evaluating how quickly and completely a treatment works. Bone marrow examination is often required, as the presence or absence of bone marrow involvement can affect eligibility for certain studies.^[1]

Blood tests performed for trial qualification are typically more extensive than those done for routine diagnosis. In addition to the standard CBC, LDH, and beta-2 microglobulin measurements, trials may require detailed assessments of liver and kidney function, since many experimental drugs are processed through these organs. Tests measuring blood clotting function, electrolyte levels, and other metabolic parameters help ensure that patients can safely tolerate the treatment being studied.^[12]

For gastric MALT lymphoma trials, documentation of Helicobacter pylori status is usually required. Many studies enroll only patients whose lymphoma has not responded to antibiotic treatment for H. pylori, or who do not have H. pylori infection. This is because antibiotic therapy can cure many cases of H. pylori-positive gastric MALT lymphoma, making additional treatment unnecessary.^[11]

Performance status assessment is another standard component of trial qualification. Doctors use standardized scales to rate how well patients can carry out daily activities and care for themselves. Most trials require that patients have good performance status, meaning they are able to be active and work at least part-time, because this indicates they are likely healthy enough to tolerate treatment.^[1]

Some trials investigating targeted therapies require specific genetic or molecular testing. For example, studies of drugs that block B-cell receptor signaling may require tests showing that the lymphoma cells have certain genetic features or express particular proteins that make them likely to respond to the treatment. These companion diagnostics help match patients to the therapies most likely to benefit them.^[9]

⚠️ Important

Clinical trials require thorough diagnostic testing to ensure patient safety and study reliability. If you are considering joining a trial, be prepared for additional tests beyond what was done for your initial diagnosis. These may include repeat biopsies, specialized genetic testing, and comprehensive imaging studies. All of these help determine if the experimental treatment is appropriate for your specific situation.

Repeat endoscopy with biopsy is common in gastric MALT lymphoma trials. This allows doctors to directly visualize the stomach lining and obtain fresh tissue samples that can be tested for specific molecular features. Some studies require that biopsies show a minimum amount of lymphoma cells to ensure that there is measurable disease that can be tracked during treatment.^[1]

Quality of life assessments, while not strictly diagnostic tests, are increasingly included as part of trial qualification. Patients complete questionnaires about their symptoms, daily functioning, and emotional well-being. These baseline measurements allow researchers to understand not just whether a treatment shrinks tumors, but also whether it improves how patients feel and function in their daily lives.^[1]

Prognosis and Survival Rate

Prognosis

MALT lymphoma generally has a favorable outlook compared to many other types of lymphoma. Because it is an indolent, or slow-growing, disease, many patients live for many years after diagnosis. The disease typically presents at an early stage, with the majority of patients having localized disease at the time of diagnosis. This localized presentation contributes to better outcomes, as treatment can be focused on the affected area.^[8]

Several factors influence the prognosis for individual patients. The location of the lymphoma plays an important role. Gastric MALT lymphoma, especially when associated with Helicobacter pylori infection, often responds very well to antibiotic treatment alone, with complete remission achieved in approximately 90 percent of cases. This makes it one of the most treatable forms of lymphoma.^[11] Non-gastric MALT lymphomas also generally have good outcomes, though they may require different treatment approaches depending on their location.

The stage of disease at diagnosis affects prognosis. Most people present with stage I or II disease, meaning the lymphoma is limited to one area or region of the body. A minority of patients have bone marrow involvement at diagnosis, which is more common in MALT lymphomas of the lung and areas around the eyes compared to gastric MALT lymphoma. The presence of disease in multiple extranodal sites, which can occur in up to 25 percent of cases, may indicate more extensive disease but does not necessarily mean a poor outcome.^[7]

Age and overall health status also matter. Patients who are otherwise healthy and have good performance status tend to tolerate treatment better and have better outcomes. Certain blood test results, such as elevated LDH or beta-2 microglobulin levels, may indicate more aggressive disease or higher disease burden and could affect prognosis.^[12]

One important consideration is the possibility of transformation. While uncommon, MALT lymphoma can sometimes change into an aggressive type called diffuse large B-cell lymphoma. This transformation is associated with a less favorable prognosis and requires more intensive treatment. Certain genetic changes, such as TP53 mutations or MYC rearrangements, may increase the risk of transformation.^[4]

Survival Rate

Studies of MALT lymphoma have shown excellent survival rates, particularly for localized disease. Research on ocular adnexal MALT lymphoma (affecting tissues around the eye) found three-year overall survival rates of 100 percent and event-free survival rates of 97 percent in patients treated with radiation therapy. This means that virtually all patients were alive three years after diagnosis, and 97 percent had not experienced disease recurrence or progression.^[13]

These outstanding results reflect the generally indolent nature of MALT lymphoma and its responsiveness to treatment. Even when the disease is more widespread, the overall outlook remains good compared to many other cancers. The slow-growing nature of MALT lymphoma means that even if complete cure is not achieved, many patients live for extended periods with their disease under control.^[15]

Long-term follow-up is important for all patients with MALT lymphoma, as the disease can recur years after initial successful treatment. However, recurrences often remain manageable with additional therapy. The overall prognosis for MALT lymphoma remains favorable, with many patients achieving long-term survival and maintaining good quality of life.^[6]

#1 Clinical Trials Search in Europe